Hospitals capitalize on oncology biosimilars; acquisition costs drop significantly while reimbursement rates enable higher profit margins and increased utilization.

by Robinson JC, Kosorukov AD and Whaley CM in JAMA

📖 read the article: https://jamanetwork.com/journals/jama/article-abstract/2846346